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Abstract: Mucous membrane pemphigoid (MMP) is an autoimmune blistering disorder that 
is characterized by subepithelial bullae. Various basement membrane zone components have 
been identiﬁ  ed as targets of autoantibodies in MMP. Considerable variability exists in the 
clinical presentation of MMP. Mucous membranes that may be involved include the oral cavity, 
conjunctiva, nasopharynx, larynx, esophagus, genitourinary tract, and anus. A multidisciplinary 
approach is essential in the management of MMP. Early recognition of this disorder and treatment 
may decrease disease-related complications. The choice of agents for treatment of MMP is 
based upon the sites of involvement, clinical severity, and disease progression. For more severe 
disease, or with rapid progression, systemic corticosteroids are the agents of choice for initial 
treatment, combined with steroid-sparing agents for long-term maintenance. Due to the rarity 
of this disease, large controlled studies comparing the efﬁ  cacy of various agents are lacking.
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Clinical ﬁ  ndings and diagnosis
Mucous membrane pemphigoid (MMP) is an autoimmune blistering disorder of 
mucous membranes that is characterized by subepithelial bullae (Chan et al 2002; Egan 
et al 2003; Thorne et al 2004). Mucous membranes that may be involved include the 
oral cavity, conjunctiva, nasopharynx, larynx, esophagus, genitourinary tract, and anus. 
The oral mucosa is most commonly involved, followed by the conjunctiva (Thorne 
et al 2004). The skin is involved in approximately one-quarter of patients (Ahmed and 
Hombal 1986), often limited to the head, neck, and upper torso regions (Figure 1).
Various basement membrane zone components have been identiﬁ  ed as targets of 
autoantibodies in MMP. These include bullous pemphigoid antigen 1 (BPAg1, 230 kd) 
(Bernard et al 1990), bullous pemphigoid antigen 2 (BPAg2, 180 kd) (Balding et al 
1996), laminin 5 (Domloge-Hultsch et al 1994), laminin 6 (Chan et al 1997), α6-integrin 
subunit (Rashid et al 2006b), β4-integrin subunit (Tyagi et al 1996), collagen VII 
(Luke et al 1999; Wieme et al 1999), and other proteins of unknown identity and/or 
function (Ghohestani et al 1996; Sarret et al 1989). There is no deﬁ  nitive evidence 
linking speciﬁ  c disease phenotypes with particular target antigens. However, a recent 
study found that sera of patients with cicatricial ocular disease and generalized MMP 
contained antibodies to β4-integrin, and sera of those with oral MMP contained anti-
bodies to α6-integrin (Rashid et al 2006a). These patients maintained selectivity to 
the target antigen throughout their clinical course.
Diagnosis of MMP rests mainly upon the clinical ﬁ  ndings and immunoﬂ  uorescence 
studies. Histopathologic examination reveals a subepithelial blister with a variable 
inﬂ  ammatory cell inﬁ  ltrate. Direct immunoﬂ  uorescence of perilesional mucosa 
or skin is essential for diagnosis, and reveals linear deposition of IgG, C3, or less 
commonly IgA along the basement membrane zone (Fine et al 1984; Leonard et al 
1988; Rogers et al 1977). The use of salt split skin or mucosal epithelium for indirect Therapeutics and Clinical Risk Management 2008:4(3) 618
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immunoﬂ  uorescence studies may increase the sensitivity of 
this technique. Indirect immunoﬂ  uorescence utilizing salt 
split skin may reveal binding to the roof and/or ﬂ  oor depend-
ing upon the antigen targeted (Ghohestani et al 1997; Kelly 
and Wojnarowska 1988).
Considerable variability exists in the clinical presentation 
of MMP. Patients may present with only one mucosal or skin 
site involved, or any combination of sites. Manifestations of 
oral disease, the most common site of involvement, include 
vesicles, erosions, desquamative gingivitis, and occasional 
scarring (Figure 2). Scarring is common at nonoral sites of 
involvement, contributing to disease-related morbidity.
Ocular complications of MMP result from conjunctival 
erosions with subsequent scarring and progressive cicatriza-
tion with foreshortening of the fornices (Elder et al 1996). The 
palpebral conjunctiva lining the lids may fuse with the bulbar 
conjunctiva, resulting in symblepharon or scar bands between 
the lid and globe (Figure 3). The scarring of the conjunctiva 
also results in loss of goblet cells with subsequent dry eye and 
disruption of the corneal epithelium (Ralph 1975).
Eyelid malposition is also a common occurrence, with 
entropion or inward turning of the lid margin resulting from 
the scarring process of the conjunctiva (Faraj and Hoang-
Xuan 2001; Shiu and McNab 2005) (Figure 4). This results 
in inadequate ocular surface protection and abrasion of the 
ocular surface by misdirected eyelashes, further compromis-
ing the corneal integrity and contributing to corneal scarring 
and neovascularization. Blindness and even loss of the globe 
due to perforation and endophthalmitis may occur (Messmer 
et al 2000; Nouri et al 2001).
Anogenital involvement presents with blisters and ero-
sions that may result in scarring. Severe vulvar scarring and 
phimosis have been reported (Frith et al 1991; Fueston et al 
2002; Goldstein et al 2005). Life-threatening complications 
may result from involvement of the larynx, esophagus, and 
rarely the lower airway (Muller and Salzer 1988; Anstey et al 
1991; Alexandre et al 2006; Gamm et al 2006).
Management
A multidisciplinary approach is essential in the management 
of MMP. Early recognition and treatment may decrease dis-
ease-related complications. In a patient who presents with 
involvement of one site, a thorough review of symptoms 
highlighting other potential areas of involvement should 
Figure 1 Vesicles and erosions on the trunk.Therapeutics and Clinical Risk Management 2008:4(3) 619
Mucous membrane pemphigoid
be obtained. The choice of agents for treatment of MMP is 
based upon the sites of involvement, clinical severity, and 
disease progression.
Unfortunately, large randomized controlled trials compar-
ing the efﬁ  cacy of various agents in the treatment of MMP 
are lacking in the literature, but there is general consensus on 
the guidelines of treatment based on clinical experience. The 
First International Consensus on MMP recommended dividing 
patients into “low-risk” and “high-risk” groups based upon the 
site(s) of involvement, with “low-risk” patients deﬁ  ned as hav-
ing only oral mucosal or oral and skin involvement (Chan et al 
2002). “High-risk” patients were deﬁ  ned as having involve-
ment of the ocular, genital, nasopharyngeal, esophageal, and/or 
laryngeal mucosae, and require more aggressive treatment.
Mild disease
For mild disease without rapid progression, dapsone may 
be initiated at 25 to 50 mg per day, increasing monthly by 
25 to 50 mg until clinical remission is achieved or until the 
maximum tolerated dose is reached (usually 200 mg per day). 
Successful use of this agent has been reported in patients 
with moderate to severe oral disease, and ocular disease as 
well (Ciarrocca and Greenberg 1999; Miserocchi et al 2002). 
Failure to develop marked improvement within approximately 
3 months should prompt consideration of another agent such 
as azathioprine, methotrexate, or cyclophosphamide if the dis-
ease is affecting a high-risk site such as the ocular surface.
Appropriate pretreatment laboratory studies must be 
performed, including a glucose-6-phosphate dehydrogenase 
level due to the risk of hemolysis. Monitoring during therapy 
is required to assess for adverse effects including dose-related 
hemolytic anemia and methemoglobinemia, and other idio-
syncratic side effects such as agranulocytosis and hepatitis 
(Raizman et al 1994; Miserocchi et al 2002; Wertheim et al 
2006). Fatal hypersensitivity syndrome has been reported 
with the use of dapsone in other disease settings (Agrawal 
and Agarwalla 2005; Kosseiﬁ   et al 2006).
Severe disease
Systemic therapy
Corticosteroids
For more severe disease, or with rapid progression, systemic 
corticosteroids are the agents of choice for initial treat-
ment, combined with steroid-sparing agents for long-term 
maintenance. Prednisone is usually given at a dose of 
1–1.5 mg/kg/day, with appropriate monitoring for side effects. 
Figure 2 Gingival erosions.Therapeutics and Clinical Risk Management 2008:4(3) 620
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Therapy with prednisone lasts several months. Accordingly, 
calcium and vitamin D supplementation, along with bisphos-
phonate therapy and baseline dual energy X-ray absorptiom-
etry (DEXA) scanning, should be considered. Once patients 
achieve and maintain clinical remission, the steroid dose is 
decreased gradually. Generally, the adjuvant immunosuppres-
sive drug is continued for approximately two years.
Cyclophosphamide
Cyclophosphamide has been the traditional steroid-sparing 
agent of choice for patients with severe disease or rapid pro-
gression. It is started in conjunction with systemic steroids 
(Brody and Pirozzi 1977; Elder et al 1995). Cyclophospha-
mide is an alkylating agent that suppresses B cell function 
greater than T cell function, and has signiﬁ  cant potential 
adverse effects such as bone marrow suppression, carci-
nogenesis, and teratogenicity (Baker et al 1987). Dosage 
usually ranges between 1 to 2.5 mg/kg/day or 50 to 200 mg 
per day when administered orally, and between 0.5 to 1 g/m2 
when given as monthly intravenous (IV) pulse therapy 
(Pandya et al 1997). IV infusion given as a three day pulse 
can be particularly helpful when rapid control is needed, for 
instance prior to ocular surface surgery (Yesudian et al 2005). 
There is evidence that cyclophosphamide is more effective 
than dapsone in controlling disease (Kirtschig et al 2002), 
but large controlled studies are lacking. Awareness of the 
potential adverse effects of cyclophosphamide is critical to 
allow appropriate monitoring during therapy.
Several other steroid-sparing agents have been used in the 
treatment of MMP. For patients with mild disease that fail 
or are intolerant of dapsone, or for those with more severe 
disease that are not candidates for therapy with cyclophospha-
mide, azathioprine and methotrexate are potential alternative 
agents (Dave and Vickers 1974; Mondino and Brown 1983; 
McCluskey et al 2004). Recent reports have also noted the 
successful use of mycophenolate mofetil in the treatment 
of MMP (Megahed et al 2001; Thorne et al 2005; Salzano 
et al 2006).
Azathioprine
Azathioprine undergoes conversion to 6-thioguanine by the 
enzyme hypoxanthine-guanine phosphoribosyltransferase. 
6-thioguanine is an active purine analog that is incorpo-
rated into DNA and RNA with subsequent inhibition of 
purine metabolism and cell division. The exact mechanism 
of immunosuppression is not known. Dosage ranges from 
Figure 3 Conjunctival inﬂ  ammation and symblepharon.Therapeutics and Clinical Risk Management 2008:4(3) 621
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1–4 mg/kg/day depending upon the patient’s thiopurine 
methyltransferase level. Azathioprine has been used effec-
tively in the treatment of autoimmune bullous diseases, 
including MMP (Dave and Vickers 1974; Tauber et al 1991). 
Bialasiewicz and colleagues (1994) reported the successful 
use of azathioprine in 9 patients undergoing nasal mucosal 
grafting to the ocular surface. Miserocchi and colleagues 
(2002) noted 32 instances of treatment-related side effects 
in 23 patients treated with azathioprine.
Knowledge of the potential adverse reactions and appro-
priate monitoring are essential for the successful use of this 
agent. Serious adverse effects include leukopenia, pancytope-
nia, infection, malignancy and drug-induced hypersensitivity 
syndrome. The most common side effects are nausea, vom-
iting, and diarrhea, which may be improved by decreasing 
the dose, taking the medication with food, or giving divided 
doses. Appropriate monitoring includes periodic complete 
blood count and liver function testing.
Methotrexate
Methotrexate is an antimetabolite that irreversibly binds to 
dihydrofolate reductase. This prevents the conversion of 
dihydrofolate to tetrahydrofolate, a cofactor necessary for the 
synthesis of nucleotides needed in DNA and RNA synthesis. 
Immunosuppression results from inhibition of DNA synthe-
sis in immunocompetent cells. McCluskey and colleagues 
(2004) reported on their use of methotrexate as a solo agent 
in the treatment of ocular MMP and drug-induced ocular 
MMP in 17 patients. Dosage ranged from 5 to 25 mg given 
as a weekly dose. Mean duration of therapy was 15 months, 
ranging from 8–22 months. Control of ocular inﬂ  ammation 
was achieved in 89% of patients with MMP and 100% of 
patients with drug-induced MMP. In a review of treatment-
related side effects in 61 patients with MMP, Miserocchi 
and colleagues (2002) reported that methotrexate had the 
least number of adverse effects compared to azathioprine, 
cyclophosphamide, and dapsone.
Serious adverse effects may occur with methotrexate 
therapy. These include hepatotoxicity (liver ﬁ  brosis and cir-
rhosis), idiosyncratic acute pneumonitis, pulmonary ﬁ  brosis, 
pancytopenia, and malignancy. Gastrointestinal complaints 
such as nausea and anorexia are the most common side 
effects, frequently reduced by daily folic acid supplementa-
tion. Periodic laboratory monitoring includes complete blood 
Figure 4 Conjunctival scarring has resulted in lower eyelid entropion.Therapeutics and Clinical Risk Management 2008:4(3) 622
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count, renal panel, and liver function testing. Consideration 
should be given for liver biopsy after a cumulative dose of 
1.5 grams, or sooner based on concomitant risk factors (such 
as prior hepatic disease, alcohol or intravenous drug abuse) 
and comorbidities (such as diabetes and obesity).
Mycophenolate mofetil
Mycophenolate mofetil inhibits the enzyme inosine mono-
phosphate dehydrogenase, blocking de novo purine synthesis. 
This results in inhibition of the proliferative response of B 
and T cells. Dosage usually ranges from 1000 to 2000 mg 
per day, but higher dosages may be required. Zurdel and 
colleagues (2001) reported the successful treatment of MMP 
in 9 of 10 eyes in 5 patients. Patients received 2000 mg 
daily and were followed for at least 1 year. Gastrointestinal 
complaints were the most common side effect, but the drug 
is generally well-tolerated. Ingen-Housz-Oro and colleagues 
(2005) reported on their experience in treating 14 patients 
with mycophenolate mofetil after dapsone failed to control 
disease. Patients received 1500 to 2000 mg daily in conjunc-
tion with dapsone. 10 of 14 patients achieved control of their 
disease, and 7 of these patients were able to decrease the dose 
of dapsone. Mycophenolate mofetil was ineffective in 4 of the 
14 patients. More studies are needed to assess the efﬁ  cacy of 
mycophenolate mofetil in the treatment of MMP.
Mycophenolate mofetil is usually well tolerated. Nausea, 
anorexia, and diarrhea may occur, and appear to be dose-
related. Laboratory monitoring includes periodic complete 
blood count due to possible medication-induced leukopenia.
Intravenous immunoglobulin
Occasionally, patients present with progressive, recalcitrant 
disease despite treatment. For patients that fail therapy with 
systemic steroids and cyclophosphamide, or for those with 
rapidly progressive disease, high-dose intravenous immuno-
globulin (IVIG) offers a therapeutic alternative. Over the last 
decade, there has been increased use of IVIG in the treatment 
of autoimmune and inﬂ  ammatory skin diseases. Multiple dif-
ferent theories have been proposed to explain the mechanisms 
of action of IVIG. These include blockage of Fc receptors, 
alteration of cytokine production, cytokine antagonism, inhi-
bition of complement-mediated damage, and neutralization of 
circulating autoantibodies (Andersson et al 1996; Jolles et al 
1998). The successful use of IVIG in the treatment of MMP 
was initially reported in two patients (Urcelay et al 1997). 
Foster and Ahmed (1999) later reported on their experi-
ence in ten patients. Four to twelve cycles were required to 
achieve complete quiescence of conjunctival inﬂ  ammation. 
In long-term follow-up of these patients, the length of therapy 
ranged from 25–43 months (Sami et al 2004). Eight of the 
ten patients ﬁ  nished their study protocol, and all maintained 
remission after gradual withdrawal of IVIG therapy.
In a nonrandomized trial of 16 patients comparing the 
use of IVIG with conventional immunosuppression, IVIG 
was found to be more effective and safer than conventional 
therapy (Letko et al 2004). Studies evaluating the cost of 
IVIG therapy versus conventional therapy, both annually and 
over the total disease course, have suggested IVIG to be more 
cost-efﬁ  cient than conventional immunosuppressive therapy 
(Daoud et al 2005; Daoud and Amin 2006). This was mainly 
attributed to the cost of treatment-related adverse effects in 
those given conventional immunosuppressive therapy. These 
ﬁ  ndings have not been conﬁ  rmed by other authors.
IVIG dosage ranges from 2 to 3 g/kg/cycle, usually 
infused in divided doses over 3 to 5 days. The frequency 
of infusion varies from every 3 to 4 weeks initially, until 
disease activity subsides. The interval between cycles 
is then gradually increased as long as clinical remission is 
maintained. The endpoint of therapy has been suggested as a 
sustained clinical remission with two cycles 16 weeks apart 
(Sami et al 2004).
The most common adverse reaction related to IVIG use 
is an infusion reaction, and symptoms may include ﬂ  ush-
ing, headache, chills, nausea, tachycardia, hypotension, and 
wheezing. The infusion should be slowed or discontinued 
based on the severity of the reaction. Premedication with an 
antihistamine and acetaminophen or intravenous steroid may 
be helpful in patients with a previous infusion reaction. Other 
rare adverse effects include anaphylaxis, disseminated intra-
vascular coagulation, thrombosis, and acute renal failure. Pre-
treatment screening labs may include complete blood count, 
renal panel, liver function tests, hepatitis panel, HIV testing, 
IgA level, rheumatoid factor, and cryoglobulins. Periodic 
assessment of complete blood count, renal and liver panels, 
and HIV and hepatitis screening should be considered.
Other treatment
Successful treatment with other relatively new agents has 
recently been reported. Antitumor necrosis factor α agents, 
such as etanercept and inﬂ  iximab, have been reported to be 
efﬁ  cacious in the treatment of recalcitrant MMP (Sacher et al 
2002; Canizares et al 2006; Heffernan and Bentley 2006). 
Daclizumab, an interleukin-2 receptor antagonist, was studied 
in a retrospective nonrandomized case series for the treatment 
of ocular inﬂ  ammatory diseases. This study included the 
successful treatment of one patient with recalcitrant MMP Therapeutics and Clinical Risk Management 2008:4(3) 623
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using daclizumab monotherapy (Papaliodis et al 2003). The 
anti-CD20 agent rituximab has been successfully utilized in 
the treatment of pemphigus vulgaris (El Tal et al 2006) and 
bullous pemphigoid (Szabolcs et al 2002), and may be a 
useful agent for treatment-resistant MMP. Further studies are 
needed to assess the efﬁ  cacy of these newer agents.
After discontinuation of systemic therapies, continued 
monitoring for disease activity is extremely important. 
Neumann and colleagues (1991) reported on their experience 
with 104 patients with MMP, noting that 22% of patients 
eventually relapsed after discontinuation of therapy. Patients 
also need to be monitored long-term for onset of disease at 
sites other than their initial areas of involvement (Thorne 
et al 2004; Higgins et al 2006).
Topical therapy
Oral disease
Topical treatments are often used as adjunctive therapy in 
the treatment of MMP, and occasionally as monotherapy in 
patients with limited oral disease. Successful treatment of 
oral lesions has been reported with the use of topical steroids, 
tacrolimus, and cyclosporine (Aufdemorte et al 1985; Eisen 
et al 1990; Lozada-Nur et al 1991; Hall et al 2003; Assman 
et al 2004; Suresh et al 2006). Topical therapy of MMP 
involving the oral mucosa can be augmented with specialized 
application devices and administration at bedtime when oral 
secretions are relatively low.
Ocular disease
Although topical therapy alone has been successful in treat-
ing limited oral involvement, topical medications are used 
only as an adjunctive measure with systemic therapy in the 
treatment of ocular disease. Topical and subconjunctival 
corticosteroids may offer palliation of symptoms, but are 
ineffective in halting disease progression (Foster 1986).
Experience in treating ocular disease with topical for-
mulations of the calcineurin inhibitors, cyclosporin A and 
tacrolimus, has been reported. Holland and colleagues (1993) 
noted lack of a therapeutic response to topical cyclosporine 
in a small series of patients. Hall and colleagues (2003), and 
more recently Michel and Gain (2006), reported successful 
use of topical tacrolimus in the treatment of one patient with 
MMP. Interestingly, systemic tacrolimus has not been found 
to be efﬁ  cacious in controlling MMP (Letko et al 2001).
Mitomycin C is an alkylating agent that has been shown to 
inhibit DNA synthesis and ﬁ  broblast proliferation. Both topical 
and subconjunctival applications of mitomycin C have been 
described in the treatment of advanced ocular disease in MMP. 
Secchi and Tognon (1996) treated ten eyes of ﬁ  ve patients 
with intraoperative topical mitomycin C after surgical lysis 
of conjunctival synechiae. After 12–19 months of follow-up, 
no recurrences were noted. Donnenfeld and colleagues (1999) 
described the use of subconjunctival mitomycin C injection 
in the more severely affected eye of 9 patients with severe 
ocular MMP. After 12–40 months of follow-up, treated eyes 
showed less conjunctival erythema and shrinkage compared 
with the untreated control eyes. In contrast, Celis Sanchez 
and colleagues (2002) found no beneﬁ  t of subconjunctival 
mitomycin C in preventing disease progression in 4 patients 
with severe ocular MMP.
Prevention of scarring and complications
Prevention of scarring and cicatrization is of utmost impor-
tance in the treatment of MMP, as surgical correction can be 
difﬁ  cult and fraught with complications. Therefore, control 
of disease progression by halting inﬂ  ammation is paramount. 
Patients should be followed by the appropriate subspecialists 
based upon the systems involved.
Oral care
Oral care includes appropriate dental hygiene, referral for 
dental care, monitoring for candidiasis, and topical anesthetics 
for pain. Soft, bland foods may cause less injury to eroded 
mucosa when disease is ﬂ  aring. Fortunately, oral disease does 
not commonly result in functionally signiﬁ  cant scarring.
Eye care
Eye care should be provided by an ophthalmologist as dis-
ease progression may be subtle. Ocular lubricants such as 
nonpreserved artiﬁ  cial tears, ointment, and gels are useful in 
improving surface lubrication. Placement of punctal plugs 
or punctal occlusion by cautery or surgery decreases tear 
drainage through the lacrimal drainage system. This can be 
helpful in increasing the tear lake, and increasing the reten-
tion of topically applied lubricants. Topical steroids may be 
used as adjunctive treatment, but should be dispensed and 
monitored by an ophthalmologist due to the risks of infec-
tion, increased intraocular pressure, and cataract. Squamous 
metaplasia with keratinization of the conjunctiva may be 
treated with topical retinoids formulated or compounded for 
use on the ocular surface.
Concomitant blepharitis should be recognized and 
treated appropriately. Classically divided into anterior and 
posterior varieties, blepharitis is an inﬂ  ammation of the 
eyelids with bacterial colonization centered on the eyelashes 
and associated follicles or meibomian glands, respectively. Therapeutics and Clinical Risk Management 2008:4(3) 624
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Blepharitis can contribute to eyelid scarring with trichiasis, 
and cause conjunctival and corneal inﬂ  ammation as well. 
Treatment consists of daily or twice daily warm compresses, 
followed by eyelid scrubs with diluted baby shampoo. 
Nightly application of a topical antibiotic ointment such as 
erythromycin or bacitracin is also helpful. For signiﬁ  cant 
conjunctival or corneal inﬂ  ammation, topical steroids in 
combination with an antibiotic are useful. For signiﬁ  cant 
meibomian gland disease with inspissation and inﬂ  ammation, 
oral tetracycline or doxycycline is often used.
Signiﬁ  cant ocular scarring from MMP resulting in func-
tional impairment may be amenable to surgical correction. 
However, repair should not be attempted until the disease 
is in remission. Premature interventions are likely to fail as 
surgical manipulation can cause ﬂ  aring of disease.
Entropion with secondary trichiasis may be treated with 
cryotherapy, marginal rotation of the eyelid, or lid splitting 
with repositioning of the lash-bearing portion of the lid mar-
gin (Elder and Bernauer 1994; Elder and Collin 1996). Surgi-
cal reconstruction of the fornices may be accomplished with 
mucous membrane grafting or amniotic membrane grafting, 
possibly augmented with topical or subconjunctival mitomy-
cin (Shore et al 1992; Barabino and Rolando 2003; Barabino 
et al 2003; Tseng et al 2005; Yesudian et al 2005).
Microbial keratitis may occur due to a combination of fac-
tors including ocular surface disease, dry eye, corneal expo-
sure, and corneal anesthesia. Prompt culture and institution of 
broad spectrum topical antibiotics are essential for prevention 
of corneal perforation and subsequent endophthalmitis. Cor-
neal perforation may also occur due to dry eye, particularly 
in combination with ocular surface inﬂ  ammation, and also 
requires immediate intervention. Treatment options include 
procedures such as suturing, cyanoacrylate glue with bandage 
contact lens placement, and corneal grafting.
Corneal transplant can restore the clarity of the visual 
axis scarred from MMP, but stem cell deﬁ  ciency, dry eye, lid 
malposition, and conjunctival inﬂ  ammation can contribute to 
graft failure or rejection (Tugal-Tutkun et al 1995; Tsubota 
et al 1996). Limbal stem cell deﬁ  ciency may be addressed with 
limbal stem cell grafting prior to corneal transplant to increase 
the success of the corneal graft. Placement of a keratoprosthe-
sis or osteo-odonto-keratoprosthesis also offers an alternative 
for patients with severe visual disability due to end-stage 
scarring (Falcinelli et al 2005; Hollick et al 2006).
Upper aerodigestive system
Upper aerodigestive complications of disease include 
atrophic rhinitis, crusting, erosions, synechiae, stenoses, and 
potentially life-threatening laryngeal stenosis (Alexandre 
et al 2006). Treatment of the nasal manifestations may 
include local steroids and irrigation. Patients should be ques-
tioned regarding any nose and throat symptoms and referred 
for otolaryngology consultation (Whiteside et al 2003). 
Dysphagia due to esophageal strictures may occasionally 
occur and can be treated with esophageal dilation (Isolauri 
and Airo 1989; Syn and Ahmed 2004).
Summary
The diagnosis of MMP remains a challenge as patients may 
present to a variety of specialists, depending upon their initial 
symptomatology, and due to the diverse clinical manifesta-
tions. Maintaining a level of suspicion for the diagnosis 
is crucial for early recognition and treatment. Due to the 
relative rarity of this disorder, large, randomized controlled 
trials comparing the efﬁ  cacy of various therapeutic agents 
are lacking. Therapy is guided by each individual patient’s 
disease course and comorbid risk factors. A multidisciplinary 
approach aids in choosing the appropriate therapy, and 
improves patient outcomes.
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